Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 7 versus TRAVASOL 5 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 7 versus TRAVASOL 5 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
AMINOSYN II 7% vs TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for protein synthesis and supports metabolic functions in patients unable to tolerate oral or enteral nutrition.
Travasol 5.5% with electrolytes provides a source of amino acids and electrolytes for parenteral nutrition, supporting protein synthesis and maintaining metabolic balance.
Intravenous infusion; typical adult dose: 0.8-1.5 g amino acids/kg/day (11.4-21.4 mL/kg/day of 7% solution); rate not exceeding 0.1 g amino acids/kg/hour.
Intravenous: 500 mL to 2 L per day, infused at a rate of 20-40 mL/kg/day (0.5-1.5 g amino acids/kg/day) based on metabolic needs and tolerance.
None Documented
None Documented
Not applicable; exogenous amino acids are rapidly cleared from plasma with a terminal half-life of 15-20 minutes for individual amino acids.
Not applicable; components are endogenous and rapidly cleared. Amino acids have short half-lives (e.g., alanine ~15 min; leucine ~30 min) and are continuously metabolized. Terminal elimination of water and electrolytes follows body fluid kinetics.
Renal as amino acids and metabolites; negligible biliary/fecal.
Primarily renal; 90-100% eliminated as free amino acids, electrolytes, and water. Metabolized nitrogen is excreted as urea. Biliary/fecal: negligible (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution